Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fluticasone

Criteria

Inclusion Criteria:

• Male and female subjects between ages of 18 to 60 in good health

• History of atopy for at least 2 years and positive skin prick test to ragweed allergen

Exclusion criteria:

• History of asthma treated with corticosteroids

• Smokers with a smoking history of > 10 pack/years or smoking in the past year

• History of chronic obstructive pulmonary disease

Other protocol-defined inclusion/exclusion criteria may apply